Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solabegron - Velicept Therapeutics

X
Drug Profile

Solabegron - Velicept Therapeutics

Alternative Names: 427353; GW-427353; GW-427353B; Solabegron; Solabegron hydrochloride

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer AltheRx; Velicept Therapeutics
  • Class Aniline compounds; Antihyperglycaemics; Benzoic acids; Obesity therapies; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome; Overactive bladder
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 29 Nov 2022 No development reported - Phase-II for Overactive bladder in USA (PO) (Controlled release)
  • 28 Jul 2019 No recent reports of development identified for preclinical development in Overactive bladder(Combination therapy) in USA (PO)
  • 02 May 2019 Velicept Therapeutics completes a phase II trial in Overactive bladder in USA (PO) in USA (NCT03594058)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top